Detection of Unknown and Rare Pathogenic Variants in Antithrombin, Protein C and Protein S Deficiency Using High-Throughput Targeted Sequencing.

NGS anticoagulant antithrombin deficiency high-throughput sequencing mutation detection rate protein C deficiency protein S deficiency

Journal

Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402

Informations de publication

Date de publication:
23 Apr 2022
Historique:
received: 21 03 2022
revised: 14 04 2022
accepted: 22 04 2022
entrez: 28 5 2022
pubmed: 29 5 2022
medline: 29 5 2022
Statut: epublish

Résumé

The deficiency of natural anticoagulants—antithrombin (AT), protein C (PC), and protein S (PS)—is a highly predisposing factor for thrombosis, which is still underdiagnosed at the genetic level. We aimed to establish and evaluate an optimal diagnostic approach based on a high-throughput sequencing platform suitable for testing a small number of genes. A fast, flexible, and efficient method involving automated amplicon library preparation and target sequencing on the Ion Torrent platform was optimized. The cohort consisted of a group of 31 unrelated patients selected for sequencing due to repeatedly low levels of one of the anticoagulant proteins (11 AT-deficient, 13 PC-deficient, and 7 PS-deficient patients). The overall mutation detection rate was 67.7%, highest in PC deficiency (76.9%), and six variants were newly detected—SERPINC1 c.398A > T (p.Gln133Leu), PROC c.450C > A (p.Tyr150Ter), c.715G > C (p.Gly239Arg) and c.866C > G (p.Pro289Arg), and PROS1 c.1468delA (p.Ile490fs) and c.1931T > A (p.Ile644Asn). Our data are consistent with those of previous studies, which mostly used time-consuming Sanger sequencing for genotyping, and the indication criteria for molecular genetic testing were adapted to this process in the past. Our promising results allow for a wider application of the described methodology in clinical practice, which will enable a suitable expansion of the group of indicated patients to include individuals with severe clinical findings of thrombosis at a young age. Moreover, this approach is flexible and applicable to other oligogenic panels.

Identifiants

pubmed: 35626216
pii: diagnostics12051060
doi: 10.3390/diagnostics12051060
pmc: PMC9139221
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Nat Rev Cardiol. 2015 Aug;12(8):464-74
pubmed: 26076949
Thromb Haemost. 2012 Apr;107(4):673-80
pubmed: 22398878
Blood. 1995 Oct 1;86(7):2598-605
pubmed: 7670104
Arterioscler Thromb Vasc Biol. 1996 Dec;16(12):1407-15
pubmed: 8977443
Ann Clin Lab Sci. 2011 Fall;41(4):397-400
pubmed: 22166512
Thromb Res. 2020 May;189:39-41
pubmed: 32151802
Arch Intern Med. 1991 May;151(5):933-8
pubmed: 2025141
Blood Adv. 2017 Jun 29;1(16):1224-1237
pubmed: 29296762
Blood. 1996 May 1;87(9):3531-44
pubmed: 8611675
Pol Arch Intern Med. 2017 Aug 9;127(7-8):512-523
pubmed: 28607330
Blood. 2016 Jun 9;127(23):2791-803
pubmed: 27084890
EJIFCC. 2016 Apr 20;27(2):130-46
pubmed: 27683526
Lancet. 1991 Aug 31;338(8766):575-6
pubmed: 1678832
Blood. 2019 Dec 5;134(23):2082-2091
pubmed: 31064749
Arterioscler Thromb Vasc Biol. 1999 Apr;19(4):1026-33
pubmed: 10195932
BMC Med Genomics. 2012 Feb 21;5:7
pubmed: 22353194
Haematologica. 2014 Mar;99(3):561-9
pubmed: 24162787
Lancet. 1995 Oct 28;346(8983):1133-4
pubmed: 7475606
Ann Intern Med. 1996 Jul 1;125(1):1-7
pubmed: 8644983
Thromb Haemost. 2007 Sep;98(3):543-56
pubmed: 17849042
Br J Haematol. 1994 May;87(1):106-12
pubmed: 7947234
Blood. 1987 May;69(5):1275-9
pubmed: 3567355
Blood. 2008 Jul 1;112(1):19-27
pubmed: 18574041
Am J Med. 2013 Sep;126(9):832.e13-21
pubmed: 23830539
Am J Hum Genet. 2000 Dec;67(6):1452-9
pubmed: 11038326
Eur J Haematol. 2015 Oct;95(4):294-307
pubmed: 25533856
Hum Genet. 1992 Aug;89(6):683-4
pubmed: 1511988
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
J Thromb Thrombolysis. 2020 May;49(4):618-629
pubmed: 32248336
Thromb Haemost. 2011 Apr;105(4):635-46
pubmed: 21264449
Clin Med (Lond). 2020 Jul;20(4):e76-e81
pubmed: 32423903
Thromb Res. 2015 May;135(5):923-32
pubmed: 25784135
Thromb Haemost. 2012 Aug;108(2):247-57
pubmed: 22627591
Thromb Haemost. 2001 Sep;86(3):809-16
pubmed: 11583312

Auteurs

Petr Vrtel (P)

Department of Medical Genetics, University Hospital Olomouc, 77900 Olomouc, Czech Republic.

Ludek Slavik (L)

Department of Hemato-Oncology, University Hospital Olomouc, 77900 Olomouc, Czech Republic.

Radek Vodicka (R)

Department of Medical Genetics, University Hospital Olomouc, 77900 Olomouc, Czech Republic.

Julia Stellmachova (J)

Department of Medical Genetics, University Hospital Olomouc, 77900 Olomouc, Czech Republic.

Martin Prochazka (M)

Department of Medical Genetics, University Hospital Olomouc, 77900 Olomouc, Czech Republic.

Jana Prochazkova (J)

Department of Hemato-Oncology, University Hospital Olomouc, 77900 Olomouc, Czech Republic.

Jana Ulehlova (J)

Department of Hemato-Oncology, University Hospital Olomouc, 77900 Olomouc, Czech Republic.

Peter Rohon (P)

Department of Medical Genetics, University Hospital Olomouc, 77900 Olomouc, Czech Republic.

Tomas Simurda (T)

National Centre of Hemostasis and Thrombosis, Department of Hematology and Transfusiology, Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin and University Hospital in Martin, 03659 Martin, Slovakia.

Jan Stasko (J)

National Centre of Hemostasis and Thrombosis, Department of Hematology and Transfusiology, Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin and University Hospital in Martin, 03659 Martin, Slovakia.

Ivana Martinkova (I)

HEMACENTRUM spol s.r.o., 32600 Pilsen, Czech Republic.

Radek Vrtel (R)

Department of Medical Genetics, University Hospital Olomouc, 77900 Olomouc, Czech Republic.

Classifications MeSH